{"id":"W4401178837","doi":"10.1182/blood.2024024631","title":"Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":127,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Obinutuzumab; Ven; IGHV@; Venetoclax; Internal medicine; Chronic lymphocytic leukemia; Gastroenterology; Chlorambucil; Population; Leukemia; Oncology; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001825683,0.0003513606,0.001136916,0.0002068077,0.0001200856,0.00006653051,0.0004371714,0.0002007445,0.00006723021],"category_scores_gemma":[0.001666322,0.0002172319,0.0006248971,0.0008027323,0.0003564866,0.00007666454,0.0001907941,0.0003249432,0.00006634901],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.08144873,"about_ca_system_score_gemma":0.09500516,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001708776,"about_ca_topic_score_gemma":0.0001147049,"domain_scores_codex":[0.9964225,0.000342078,0.001016276,0.0007167268,0.0008147335,0.0006877188],"domain_scores_gemma":[0.9966815,0.001444626,0.0001783638,0.001253012,0.0002474572,0.0001950315],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8673036,0.005365117,0.00006924615,0.01508422,0.02051701,0.00277046,0.01645643,0.003965498,0.02442335,0.001834814,0.0270701,0.01514013],"study_design_scores_gemma":[0.9036418,0.002228516,0.00001045065,0.001052496,0.003132176,0.0002652797,0.0002005585,0.06348215,0.02364224,0.0001128222,0.002023473,0.0002080054],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9823791,0.005820149,0.00004560082,0.0000902172,0.0003641304,0.009530389,0.0001134976,0.0002237796,0.001433119],"genre_scores_gemma":[0.9938217,0.0002593298,0.0001086819,0.00003366494,0.0004960115,0.0007787231,0.00006475614,0.00009713682,0.004339947],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05951665,"threshold_uncertainty_score":0.9220774,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01833361852785721,"score_gpt":0.3242953708562311,"score_spread":0.3059617523283739,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}